MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Clinical trials for MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE explained in plain language.
Never miss a new study
Get alerted when new MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE trials appear
Sign up with your email to follow new studies for MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Crohn's sufferers: phase 3 trial of afimkibart launches
Disease control Recruiting nowThis study tests a new drug, Afimkibart, in 600 people with moderate to severe Crohn's disease who haven't responded well to other treatments. Half will get the drug, half a placebo, to see if it can reduce symptoms and heal the gut lining. The goal is to control the disease long…
Matched conditions: MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
New hope for Crohn's sufferers: experimental drug enters final testing phase
Disease control Recruiting nowThis study tests a new drug called RO7790121 (Afimkibart) in about 425 people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can reduce symptoms and heal the gut lining compared to a placebo. Participants wil…
Matched conditions: MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 06, 2026 16:14 UTC